US12083270 — Delivery device and method
Method of Use · Assigned to Optinose Inc · Expires 2031-04-04 · 5y remaining
What this patent protects
This patent protects a nasal delivery device and method for delivering a substance to the middle meatus in a nasal cavity for treating inflammatory or infectious conditions.
USPTO Abstract
A nasal delivery device for and method of delivering substance to the middle meatus in a nasal cavity of a subject in the treatment of a condition, in particular an inflammatory or infectious condition, thereof, the delivery device comprising: a nosepiece unit ( 17 ) including a nosepiece ( 20 ) for fitting to a nostril of a subject and a nozzle ( 25 ) through which substance is in use delivered to the respective nasal cavity; and a delivery unit ( 29 ) for delivering substance through the nozzle of the nosepiece; wherein the delivery device is configured to provide for deposition of a significant fraction of the delivered dose on, around and in the vicinity of the middle meatus.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2133 |
— | Cutivate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.